← SynDRA
LY-2584702
SynDRA canonical compound SYN0038218 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | RPS6KB1 |
|---|
| Mechanism of action | ribosomal protein inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- RPS6KB1 INHIBITOR
- Ribosomal protein S6 kinase 1 inhibitor
- ribosomal protein inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- RPS6KA6
- RPS6KA1
- RPS6KA3
- RPS6KA4
- RPS6KA5
- AAK1
- PEBP1
- PDXK
- PDGFRB
- PGRMC1
- PAK4
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK1
- PFKP
- PHKG2
- NLK
- PRKAA1
- PRKCA
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PLK4
- PIM1
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIP4K2A
- PIM2
- NQO2
- NEK9
- PRKCD
- MAPK11
- MAPK9
- MAPK8
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- GAMT
- GNMT
- HNMT
- NNMT
- PNMT
- RPS6KA2
- RPS6KB2
Cross-references
Synonyms
- LY 2584702
- LY2584702
- LY-S6K1
- LY-S6K1 HCl
- LY-S6K1 tosylate
- P70 S6 kinase inhibitor (cancer), Eli Lilly
- I4965C6W4O
- RefChem:154540
- p70S6K Inhibitor LY2584702
- LY-2584702 free base
- UNII-I4965C6W4O
- LY-2584702 (free base)
- C21H19F4N7
- SCHEMBL311369
- GTPL8248
- orb1301024
- orb1713724
- SCHEMBL29493101
- GLXC-90360
- HMS3673E19
- HMS3743I21
- EX-A2213
- BDBM50271976
- NSC800787
- s7698
- AKOS025404702
- LY2584702; LYS6K2
- CCG-269181
- CS-3596
- NSC-800787
- NCGC00386428-01
- NCGC00386428-05
- NCGC00386428-06
- NCGC00386428-09
- AC-35412
- DA-55103
- FL103547
- HY-12493
Look up LY-2584702 in the interactive SynDRA portal →